Atazanavir 300 mg

DRUG3 trials

Sponsors

Boehringer Ingelheim, GlaxoSmithKline, ViiV Healthcare

Conditions

HIV InfectionsHealthy VolunteerInfection, Human Immunodeficiency Virus

Phase 1

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

CompletedNCT00883935

GlaxoSmithKlineHealthy Volunteer

Start: 2009-04-30End: 2009-06-30Updated: 2009-06-22

Phase 2

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

CompletedNCT01384734

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2011-07-26End: 2017-05-12Updated: 2018-11-14

Phase 4

Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

CompletedNCT00552240

Boehringer IngelheimHIV Infections

Start: 2007-09-30Updated: 2014-01-27

Related Papers

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.

2022-03-228 citations

Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Antiretroviral-Experienced Subjects: Week 48 Analysis of AI438011, a Phase IIb, Randomized Controlled Trial

Antiviral Therapy2016-04-0130 citations

Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529

Antimicrobial Agents and Chemotherapy2016-02-2321 citations

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.

2015-09-0149 citations